Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 4/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 5/20 | 0.40 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GJB2 | P29033 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24670890 | 0.84 | GBA1 (0.48) | GBA1SPHK1SPHK2ALDH1A1TDP1 | |
| SCHEMBL24177516 | 0.84 | GBA1 (0.48) | GBA1SPHK1SPHK2ALDH1A1TDP1 | |
| SCHEMBL31236147 | 0.84 | GBA1 (0.48) | GBA1SPHK1SPHK2ALDH1A1TDP1 | |
| SCHEMBL14554178 | 0.83 | GBA1 (0.41) | GBA1SPHK1SPHK2MAPK1GJB2 | |
| SCHEMBL11890588 | 0.82 | ALDH1A1 (0.53) | GBA1SPHK1SPHK2ALDH1A1TDP1 | |
| SCHEMBL11318239 | 0.79 | GBA1 (0.46) | GBA1SPHK1SPHK2ALDH1A1TDP1 | |
| SCHEMBL11318242 | 0.79 | GBA1 (0.46) | GBA1SPHK1SPHK2ALDH1A1TDP1 | |
| SCHEMBL19297383 | 0.78 | GBA1 (0.40) | GBA1SPHK1SPHK2MAPK1 | |
| SCHEMBL14413940 | 0.78 | GBA1 (0.40) | GBA1SPHK1SPHK2MAPK1 | |
| SCHEMBL6984403 | 0.78 | GBA1 (0.41) | GBA1SPHK1SPHK2GJB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3202760-B1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | ALNYLAM PHARMACEUTICALS INC (US) | 2019-08-21 | — | — | EP | disclosed |
| EP-3202760-B1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | ALNYLAM PHARMACEUTICALS INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-9999673-B2 | PEGylated lipids and their use for drug delivery | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-9999673-B2 | PEGylated lipids and their use for drug delivery | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-9999673-B2 | PEGylated lipids and their use for drug delivery | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| EP-3202760-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | Alnylam Pharmaceuticals, Inc. (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-3202760-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | Alnylam Pharmaceuticals, Inc. (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-2663548-B1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | ALNYLAM PHARMACEUTICALS INC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20140200257-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-07-17 | — | — | US | disclosed |
| US-20140200257-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-07-17 | — | — | US | disclosed |
| EP-2663548-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | Alnylam Pharmaceuticals, Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| WO-2012099755-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012099755-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200257-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | LIPG, EGFR, LDLR | GBA1 307/4885SPHK1 637/4885SPHK2 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.